Allos Therapeutics, Inc. (NASDAQ:ALTH) will unveil its latest earnings on Thursday, August 4, 2011. Allos Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer.
Allos Therapeutics, Inc. Earnings Preview Cheat Sheet
Wall St. Earnings Expectations: The average estimate of analysts is for a loss of 14 cents per share, a narrower loss from the year earlier quarter net loss of 19 cents. The average estimate is the same as three months ago. Between one and three months ago, the average estimate was unchanged and it has not changed during the last month.
Past Earnings Performance: The company has beaten estimates the last four quarters and is coming off a quarter where it topped forecasts by one cent, reporting net loss of 14 cents per share against a mean estimate of a loss of 15 cents per share.
Wall St. Revenue Expectations: On average, analysts predict $11.9 million in revenue this quarter, a rise of 51.1% from the year ago quarter. Analysts are forecasting total revenue of $49.5 million for the year, a rise of 40.5% from last year’s revenue of $35.2 million.
Analyst Ratings: Analysts seem relatively indifferent about Allos Therapeutics with five of seven analysts surveyed maintaining a hold rating.
The company’s revenue has now risen for two straight quarters. In first quarter, revenue increased 46.7% to $10.9 million from the year earlier quarter. In the fourth quarter of the last fiscal year, the figure rose more than threefold.
Competitors to Watch: Seattle Genetics, Inc. (NASDAQ:SGEN), Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), Hospira, Inc. (NYSE:HSP), Mylan Inc. (NASDAQ:MYL), Cell Therapeutics, Inc. (NASDAQ:CTIC), Cephalon, Inc. (NASDAQ:CEPH), Celgene Corporation (NASDAQ:CELG), Biogen Idec Inc. (NASDAQ:BIIB).
Stock Price Performance: During May 4, 2011 to July 29, 2011, the stock price had fallen 98 cents (-34.5%) from $2.84 to $1.86. The stock price saw one of its best stretches over the last year between November 12, 2010 and November 22, 2010 when shares rose for seven-straight days, rising 12.9% (+52 cents) over that span. It saw one of its worst periods between November 22, 2010 and December 3, 2010 when shares fell for nine-straight days, falling 13.4% (-61 cents) over that span. Shares are down $2.75 (-59.7%) year to date.
(Source: Xignite Financials)